



**U.S. FOOD & DRUG**  
ADMINISTRATION

## **CBER-CDER Data Standards Program Action Plan**

**Version: 2.1**

**FY2025 Q4 update**

**Document Date: 12/23/2025**

**REVISION HISTORY**

Version Number	Revision Date	Description of Change
1.0	January 25, 2023	Revision of document structure to align with FY23-FY27 CBER-CDER Data Standards Strategic Goals
1.1	May 9, 2023	<ul style="list-style-type: none"><li>• FDA Data Standards Catalog added to Goal 2</li><li>• IDMP Guidance added to Goal 2</li><li>• Technical Specifications and Conformance Guide Updates removed from Goal 4</li><li>• Appendix B updated</li></ul>
1.2	August 14, 2023	<ul style="list-style-type: none"><li>• IDMP Guidance removed from Goal 2</li></ul>
1.3	November 9, 2023	<ul style="list-style-type: none"><li>• Quarterly Project Updates</li></ul>
1.4	February 15, 2024	<ul style="list-style-type: none"><li>• Added 356H Modernization Project under Goal 1 Objective 1</li><li>• Removed Submission Data Standards Assessment Project from Goal 1 Objective 1</li><li>• Added Publication of Final Guidance for Industry “Data Standards for Drug and Biological Product Submissions Containing Real-World Data” Project under Goal 2</li><li>• Added “Dataset JSON” as its own project under Goal 1 Objective 1</li></ul>
1.5	May 8, 2024	<ul style="list-style-type: none"><li>• Added Common Data Model Harmonization (CDMH) under Goal 1 Objective 1</li></ul>

Version Number	Revision Date	Description of Change
		<ul style="list-style-type: none"> <li>Removed Source Data Captures from EHRs: Using Standardized Clinical Research Data from Goal 1 Objective 1</li> <li>Removed Publication of Final Guidance for Industry “Data Standards for Drug and Biological Product Submissions Containing Real-World Data” from Goal 2</li> </ul>
1.6	August 9, 2024	<ul style="list-style-type: none"> <li>Removed Grant: Investigating Support for 21 CFR 11 Compliance Using HL7 FHIR from Goal 1 Objective 1</li> </ul>
1.7	November 20, 2024	<ul style="list-style-type: none"> <li>Quarterly Project Updates</li> </ul>
1.8	March 2025	<ul style="list-style-type: none"> <li>Quarterly Project Updates</li> <li>Removed FDA Adverse Event Reporting System (FAERS) II Project</li> <li>Removed eCTD v4.0 Project – Phase 1</li> </ul>
1.9	August 2025	<ul style="list-style-type: none"> <li>Quarterly Project Updates</li> <li>Reporting paused for the following projects: <ul style="list-style-type: none"> <li>Study Data Standards Testing and Evaluation</li> <li>Post Approval Changes Rulemaking &amp; Submission Standards</li> </ul> </li> </ul>
2.0	September 2025	<ul style="list-style-type: none"> <li>Quarterly Project Updates</li> </ul>
2.1	December 2025	<ul style="list-style-type: none"> <li>Quarterly Project Updates</li> <li>Removed the Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Data Standardization Project</li> </ul>

## Table of Contents

Purpose.....	5
Program Goals and Initiatives .....	5
Goal 1: Improve Data Standards for Regulatory Use .....	7
Goal 2: Data Standards Policy .....	15
Goal 3: Efficient Information Management .....	17
Goal 4: Enhance Transparency and Promote Stakeholder Engagement .....	18
Appendix A: Project Stage Definitions.....	19
Appendix B: Glossary of Acronyms .....	20

## Introduction

The purpose of the *CBER-CDER Data Standards Strategy* is to reinforce the ongoing commitment to the development, implementation, and maintenance of a comprehensive data standards program that will facilitate the pre- and post-market regulatory review process so that safe and effective medical products are available to patients.

This action plan aligns to the CBER-CDER Data Standards Strategy and reflects progress in CBER and CDER towards the defined goals and objectives. Projects selected for this action plan have started, are resourced and funded, and have a scope that is primarily standards related.

## Purpose

This action plan provides a quarterly update to internal and external stakeholders, with an overview and progress update of current data standards initiatives. The plan will continue to be updated quarterly to reflect progress of current projects, as well as initiation of new projects. For information on prior quarters, refer to previous versions of the [Action Plan](#).

## Program Goals and Initiatives

The program goals are derived from the major areas of regulatory business activities. A detailed description of these major areas can be found in the [CBER-CDER Data Standards Strategy](#).

The CBER-CDER Data Standards Program goals focus on four areas:

- Goal 1: Improve Data Standards for Regulatory Use
- Goal 2: Data Standards Policy
- Goal 3: Efficient Information Management
- Goal 4: Enhance Transparency and Stakeholder Engagement

The successful accomplishment of these goals may be achieved given sufficient resources, regulatory/legislative factors, and collaboration with stakeholders.

For each project in this section, the project title, description, update, and project stage(s) are provided. The project update reflects work done in the previous quarter (e.g., the FY2023 Q1 report highlights work from October to December 2022).

The project stage lists the typical stages a project might address during work for the project and are generally conducted in sequence from left to right. The definitions of the project stage are defined in **Appendix A**.

Project Stage
Requirements (REQT)
Analyze Alternatives (ALT)
Development (DEV)
Testing (TEST)
Adoption (ADOPT)
Implementation (IMPL)
Policy Coordination (POLICY)

Project Stage Status
In Progress
Pending
Complete
Not Applicable

## Goal 1: Improve Data Standards for Regulatory Use

Projects related to Goal 1 address our continued collaboration with Standards Development Organizations to improve data standards and support initiatives for the adoption and adaptation of new and existing standards.

### OBJECTIVE 1: Enhancement of Submission Formatting & Review

Project Title & Description	Project Status	REQT	ALT	DEV	TEST	ADOPT	IMPL	POLICY
<b>Assessing Applicable Data Standards for Use in Submission of Real-World Data to FDA</b>  FDA is examining how to optimize data standards for Real-World Data (RWD) that is submitted as study data in applicable FDA submissions. This effort will help develop a roadmap to facilitate the development of such data standards.	<b>Q4:</b>  Final report, including gap analysis and specific enhancements proposals, completed.	In Progress	In Progress	Complete	Complete	Pending	Pending	Pending

Project Title & Description	Project Status	REQT	ALT	DEV	TEST	ADOPT	IMPL	POLICY
<p><b>Common Data Model Harmonization (CDMH)</b></p> <p>This project aims to build a data infrastructure for conducting patient-centered outcomes research using Real-World Data (RWD) derived from the delivery of health care in routine clinical settings. This project started in 2017, is currently in <a href="#">Phase III</a> (2023-2025) and is a multi-HHS agency initiative, funded by HHS/Assistant Secretary for Planning and Evaluation (ASPE) Patient-Centered Outcomes Trust Fund (PCORTF).</p>	<p><b>Q4:</b></p> <p>Developed the protocol for the cancer use case in collaboration with the oncologists at CDER/OND.</p> <p>Developed a Fast Healthcare Interoperability Resources (FHIR)-based query for the CDER clinical question.</p> <p>Provided the clinical question conforming to the FHIR standard to 2 Health Information Exchanges (HIE), participating in this project, who ran the clinical query on their clinical data repository and provided the results conforming to the HL7 FHIR standard in HL7 FHIR format.</p> <p>Received the results to the cancer use case from the participating Health Information Exchanges (HIEs).</p> <p>Analyzed the results received.</p> <p>Finalized the final project report for HHS/ASPE and submitted it to HHS/ASPE.</p> <p>Validated the HL7 FHIR model, that will be registered by NCI team.</p> <p>Validated the CDISC SDTM model, that will be registered by the NCI team in caDSR.</p> <p>Reviewed and validated mappings from HL7 FHIR US Core model to CDISC SDTM. These mappings will be posted in a publicly available metadata registry and repository managed by the National Cancer Institute (NCI).</p>	Complete	Complete	Complete	Complete	Pending	Pending	Pending



Project Title & Description	Project Status	REQT	ALT	DEV	TEST	ADOPT	IMPL	POLICY
<b>Dataset-JSON Exchange Format</b>  This CBER & CDER project is a continuation of the collaboration with PHUSE and CDISC to test the use of CDISC Dataset-JSON as a potential replacement for XPT v5.	<b>Q4:</b>  No updates in Q4.	Complete	Complete	In Progress	In Progress	Pending	Pending	Pending
<b>eCTD v4.0 Project – Phase 2 (Forward Compatibility)</b>  This CBER-CDER project is focused on the development, testing, adoption, and implementation of Forward Compatibility (FC). FC enables any dossier that started in eCTD v3.2.2 to transition to eCTD v4.0.	<b>Q4:</b>  Testing paused while FDA waits for next software release. Once received, FDA will test FC functionality and work with eCTD vendor to resolve any issues, if needed. Plan to be in production, supporting FC, in Fall 2026.	Not Applicable	Not Applicable	In Progress	In Progress	Pending	Pending	Pending

Project Title & Description	Project Status	REQT	ALT	DEV	TEST	ADOPT	IMPL	POLICY
<b>IDMP Project</b>  The International Organization for Standardization (ISO) Identification of Medicinal Products (IDMP) standards aim to harmonize specifications for the identification and exchange of medicinal product data between regulatory agencies, pharmaceutical companies, and manufacturers. This project has multiple use cases focused on the adoption of ISO Identification of Medicinal Product (IDMP) standards: 1. Medicinal Product ID (MPID), 2. Substance ID (SubID), 3. Pharmaceutical Product ID (PhPID), 4. Route of Administration, Dosage Form, and 5. Units of Measure. These ISO standards define medicinal product information for regional and global data sharing. Generally, the use cases focus on safety (e.g., ICSRs) and can support quality (e.g., PQ/CMC). Additionally, the Global IDMP Working Group (GIDWG) has been engaged with ISO and other regulators to ensure the standards are fit for global implementation.	<b>Q4:</b>  IPRP (IDMP WG) — IDMP FAQ Version 7.0 published (2025) as a living document intended to support implementation of the ISO IDMP standards. The finalized Version 2.0 of the business rules was also released. The Uppsala Monitoring Centre (UMC) is a major contributor to global IDMP implementation efforts, particularly in developing and maintaining unique global product and substance identifiers.  Three key focus areas of IDMP implementation are: 1. Drug shortage prevention and response, 2. Post-market surveillance (PMS) for drug safety and pharmacovigilance, and 3. Exchange of prescription information. The European Medicines Agency (EMA) has implemented the European Shortages Monitoring Platform (ESMP) using IDMP/PhPID to enhance monitoring and management of medicine shortages. It became mandatory in 2025.  Milestone update: IDMP/PhPID concepts were adopted within the FDA Substance Registration System as part of the FDA’s Unique Ingredient Identifier (UNII) framework. While FDA participates in global IDMP standards development, the use of compatible terminology systems of global PhPIDs remains an ongoing process.	Complete	Not Applicable	Complete	In Progress	Pending	Not Applicable	Not Applicable

Project Title & Description	Project Status	Project Stages
<p><b>Questionnaires, Ratings and Scales (QRS) Assessment</b></p> <p>This CDER project is focused on evaluations of proposed standardized data structures (supplements) that capture the information from Questionnaires, Ratings, and Scales (instruments) administered to subjects during a clinical study and prioritize the instruments indicated in the Clinical Outcomes Assessment (COA) area.</p>	<p><b>Q4:</b></p> <p>Two (2) tests initiated for supplements covering these instruments:</p> <ul style="list-style-type: none"> <li>- SDS- Rising From Floor v1.0</li> <li>-Hamilton Depression Rating Scale 17 (HAMD-17) v1.0 - ADaM</li> </ul> <p>Two (2) tests completed for supplements covering these instruments:</p> <ul style="list-style-type: none"> <li>- Hamilton Depression Rating Scale 17 (HAMD-17) v1.0 – ADaM</li> <li>- Rising From Floor v1.0</li> </ul>	<p><b>Not Applicable</b></p>

Project Title & Description	Project Status	REQT	ALT	DEV	TEST	ADOPT	IMPL	POLICY
<b>SPL FHIR</b>  FDA is working towards replacing Structured Product Labeling (SPL) with HL7 FHIR. The FDA has created a proof-of-concept system that can receive labeling information using either SPL or FHIR standard (Dual Submission) in addition to a draft Implementation Guide (IG).	<b>Q4:</b>  Contract expired and further work on this project has been halted.	Complete	Complete	Complete	Complete	Pending	Pending	Pending

Project Title & Description	Project Status	Project Stages
<b>Study Data Standards Testing and Evaluation</b>  This CBER-CDER project tests new and updated study data standards and standards adjacent properties to establish FDA support and requirements.	<b>Q4:</b>  No updates in Q4.	Not Applicable

Project Title & Description	Project Status	REQT	ALT	DEV	TEST	ADOPT	IMPL	POLICY
<b>356H Modernization</b>  This project will be assessing feasibility and working towards development of a machine-readable approach for receiving the data requested in Form FDA 356h.	<b>Q4:</b>  No updates in Q4.	In Progress	Pending	Pending	Pending	Pending	Pending	Pending

## OBJECTIVE 2: Improve Pre and Postmarket Safety Surveillance Data

Project Title & Description	Project Status	REQT	ALT	DEV	TEST	ADOPT	IMPL	POLICY
<p><b>Biologics Effectiveness and Safety (BEST) Innovative Methods (IM)</b></p> <p>Leverages Artificial Intelligence, Machine Learning, FHIR standards and SMART-on-FHIR to develop a semi-automated adverse event (AE) reporting system from EHRs. The system uses such innovative methods to detect exposures/outcomes of biologics and facilitates validation and reporting of flagged cases to the FDA. Project goals include development of tools, methods and techniques needed to reduce the burden on providers to report AEs accurately and efficiently, which is critical to strengthen the post market active surveillance program of CBER regulated products.</p>	<p><b>Q4:</b></p> <p>The BEST platform has been deployed On-Prem (in the HIVE environment) to facilitate FDA SMEs access to the BEST IM Platform and started the authorization to operate (ATO) process.</p> <ul style="list-style-type: none"> <li>-Completed validation of large language model-enhanced computable phenotype algorithm employing FHIR resources for myocarditis and pericarditis</li> <li>-Initiated creation of post-CAR-T hypogammaglobulinemia computational phenotype</li> <li>-Collaborate with one large academic medical center to pull FHIR resources for hypogammaglobulinemia</li> </ul>	Complete	Complete	Complete	Complete	Complete	In Progress	Pending

## Goal 2: Data Standards Policy

Projects aligned under Goal 2 provide governance and expertise for the development and revision of data standards policies related to the regulation of human drugs and biological products. The continued implementation and refining of governance processes ensure proper oversight during the development, publication, and maintenance of guidance documents detailing the use of data standards, terminologies, and exchange formats for regulatory submissions.

Project Title & Description	Project Status	Project Stages
<b>FDA Data Standards Catalog</b>	<b>Q4:</b>  No updates in Q4.	Ongoing Updates

Project Title & Description	Project Status	REQT	ALT	DEV	TEST	ADOPT	IMPL	POLICY
<b>Post Approval Changes Rulemaking &amp; Submission Standards</b>  This CBER-CDER project is focused on improving the usability of post approval submissions data.	<b>Q4:</b>  The rulemaking proposal is listed in the Spring 2025 Unified Agenda of Regulatory and Deregulatory Actions with an action date of 05/00/2026 for a Notice of Proposed Rulemaking.	Complete	Not Applicable	In Progress	Not Applicable	Not Applicable	Not Applicable	Pending

Project Title & Description	Project Status	Project Stages
<b>Study Data Technical Conformance Guide (sdTCG)</b>	<b>Q4:</b> No updates in Q4.	Ongoing Semi-Annual Publications



### **Goal 3: Efficient Information Management**

Projects aligned under Goal 3 promote efficient review process because the data submitted is in a predictable and consistent format that can be more easily used by analytic systems.

As outlined in the [CBER-CDER Data Standards Strategy](#) document, technology is critically important and serves as an enabler for reviewers to access and use large amounts of data and information that is received and generated. Several data standards development projects are already underway, as highlighted earlier in this document, to promote access to high-quality, standardized data including the PQ/CMC Standardization and IDMP projects. CDER and CBER also continues to define and enhance ways to better capture information created internally to support continued knowledge management activities. Progress towards the Goal 3 objectives will be highlighted annually in the Data Standards Program Annual Assessment and not tracked quarterly.

## Goal 4: Enhance Transparency and Promote Stakeholder Engagement

Efforts supported under Goal 4 enhance transparency and promote stakeholder engagement in its decision-making regarding adoption of new standards, especially required standards. In addition, these efforts are promoted through the following activities:

Program Operations	Updates
Action Plan	FY2025 Q3 published September 26, 2025.
Annual Assessment	2024 Annual Assessment published on July 8, 2025.
eCTD Submission Standards	Updates to Specification for File Format Types Using eCTD Specifications, published August 20, 2025.
Outreach Opportunities, Public Meetings & Educational Activities	FDA Webinars are planned to focus on various data standards topics.

## Appendix A: Project Stage Definitions

Stage Name	Stage Description
<b>Requirements</b>	A project with the objective of developing a standard, or utilizing an existing standard for the receipt, processing, review, and archive of data used in regulatory review is considered a data standards project.
<b>Analyze Alternatives</b>	A project's approach to the identification and analysis of alternatives to solve a data standards problem.
<b>Development</b>	The approach to address approved changes to data standards or data standards policy.
<b>Test</b>	A project may be required to test (CDER) study data standards that is adaptable based on the situation. Provides a process to determine if a standard meets the needs of the FDA and should be accepted by the FDA.
<b>Determine Data Standard Adoption (Adoption)</b>	The project is approved and proceeds towards the adoption.
<b>Implement Standard (Implementation)</b>	The advancement to implementing an approved data standard need or change.
<b>Policy</b>	FDA may publish an FRN or guidance, as well as relevant technical specifications or technical conformance guides, as needed.

## Appendix B: Glossary of Acronyms

Acronym	Definition
ADaM	Analysis Data Model
AE	Adverse Events
Catalog	FDA Data Standards Catalog
CBER	Center for Biologics Evaluation and Research
CDER	Center for Drug Evaluation and Research
CDISC	Clinical Data Interchange Standards Consortium
COA	Clinical Outcomes Assessment
eCTD	Electronic Common Technical Document
EHR	Electronic Health Record
FHIR	Fast Healthcare Interoperability Resource
FRN	Federal Register Notice
FY	Fiscal Year
GSRS	Global Substance Registration System
HL7	Health Level Seven
ICH	International Council for Harmonization
ICSR	Individual Case Safety Report
IDMP	Identification of Medicinal Product
IND	Investigational New Drug Application
ISO	International Organization for Standardization
PDUFA	Prescription Drug User Fee Act
PQ/CMC	Pharmaceutical Quality/Chemistry, Manufacturing, and Controls
QRS	Questionnaires, Ratings, and Scales
SDTM	Study Data Tabulation Model
SDTMIG	Study Data Tabulation Model Implementation Guide
SEND	Standard for Exchange of Nonclinical Data
SENDIG	Standard for Exchange of Nonclinical Data Implementation Guide
SENDIG-AR	Standard for Exchange of Nonclinical Data Implementation Guide: Animal Rule
SPL	Structured Product Labeling

Acronym	Definition
sdTCG	Study Data Technical Conformance Guide
TAUG	CDISC Therapeutic Area User Guide
TCG	Technical Conformance Guide
UMC	Uppsala Monitoring Centre
UNII	Unique Ingredient Identifier